NovoCure's Accounts Payables rose 3022.7% to $118.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.9 million, marking a year-over-year increase of 3022.7%. This contributed to the annual value of $105.1 million for FY2024, which is 1133.05% up from last year.
Latest data reveals that NovoCure reported Accounts Payables of $118.9 million as of Q3 2025, which was up 3022.7% from $103.7 million recorded in Q2 2025.
In the past 5 years, NovoCure's Accounts Payables ranged from a high of $118.9 million in Q3 2025 and a low of $52.7 million during Q1 2021
Over the past 5 years, NovoCure's median Accounts Payables value was $82.5 million (recorded in 2023), while the average stood at $83.2 million.
Per our database at Business Quant, NovoCure's Accounts Payables skyrocketed by 4747.05% in 2021 and then soared by 328.62% in 2023.
Over the past 5 years, NovoCure's Accounts Payables (Quarter) stood at $72.6 million in 2021, then rose by 17.35% to $85.2 million in 2022, then grew by 10.79% to $94.4 million in 2023, then grew by 11.33% to $105.1 million in 2024, then rose by 13.17% to $118.9 million in 2025.
Its last three reported values are $118.9 million in Q3 2025, $103.7 million for Q2 2025, and $95.1 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value